12.10.20: Not intended for U.S. and UK Media - American Society of Nephrology (ASN)'s Kidney Week 2020 Reimagined:

Finerenone Phase III FIDELIO-DKD study in chronic kidney disease and type 2 diabetes to be presented as late-breaking clinical trial at ASN 2020FIDELIO-DKD is the first large contemporary positive outcomes study in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) with a primary composite endpoint consisting exclusively of kidney-specific outcomes / Finerenone, a first-in-class investigational non-steroidal, selective mineralocorticoid receptor (MR) antagonist, demonstrated positive renal and cardiovascular outcomes in patients with CKD and T2D / Preclinical data on finerenone, as well as a range of poster presentations in cardiovascular and kidney diseases will be presentedmehr ...
Source: Bayer IR Newsfeed: Events - Category: Pharmaceuticals Source Type: news